Research Highlights: In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by...
  • pound_heap@lemmy.dbzer0.comEnglish
    0·
    4 months ago

    was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by about 55%

    From the referenced article